STERIS (STE) Set to Post Earnings on Wednesday

STERIS (NYSE:STE) is expected to issue its Q2 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $2.67 per share and revenue of $1.56 billion for the quarter. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Individuals may review the information on the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.10. The company had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.49 billion. STERIS had a return on equity of 14.34% and a net margin of 13.34%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.34 earnings per share. On average, analysts expect STERIS to post $11.17 EPS for the current fiscal year and $12.40 EPS for the next fiscal year.

STERIS Stock Performance

Shares of STERIS stock opened at $233.40 on Tuesday. The company has a market capitalization of $22.76 billion, a PE ratio of 28.53 and a beta of 0.92. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.35 and a current ratio of 1.91. The company has a 50-day simple moving average of $219.72 and a two-hundred day simple moving average of $225.07. STERIS has a one year low of $195.14 and a one year high of $269.44.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Tuesday, November 17th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, November 17th. STERIS’s dividend payout ratio (DPR) is currently 33.74%.

Wall Street Analysts Forecast Growth

STE has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of STERIS in a research report on Monday, August 24th. Piper Sandler reissued an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 11th. Finally, UBS Group lowered their target price on shares of STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $271.33.

Insider Buying and Selling at STERIS

In other news, Director Mohsen Sohi sold 4,058 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the transaction, the director owned 24,305 shares in the company, valued at $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.12% of the company’s stock.

STERIS Company Profile

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.